Lipoprotein-associated phospholipase A2, a marker of vascular inflammation and systemic vulnerability

Expression of lipoprotein-associated phospholipase A2 in carotid artery plaques predicts long-term cardiac outcome

(2009) J. Herrmann et al.   EUROPEAN HEART JOURNAL

Consensus Panel Recommendation for Incorporating Lipoprotein-Associated Phospholipase A2 Testing into Cardiovascular Disease Risk Assessment Guidelines

(2008) Michael H. Davidson et al.   AMERICAN JOURNAL OF CARDIOLOGY

Review of the Evidence for the Clinical Utility of Lipoprotein-Associated Phospholipase A2 as a Cardiovascular Risk Marker

(2008) Marshall A. Corson et al.   AMERICAN JOURNAL OF CARDIOLOGY

Biology of Platelet-activating Factor Acetylhydrolase (PAF-AH, Lipoprotein Associated Phospholipase A2)

(2008) Diana M. Stafforini   CARDIOVASCULAR DRUGS AND THERAPY

Phospholipase A2 Biochemistry

(2008) John E. Burke et al.   CARDIOVASCULAR DRUGS AND THERAPY

Effects of the Direct Lipoprotein-Associated Phospholipase A 2 Inhibitor Darapladib on Human Coronary Atherosclerotic Plaque

(2008) Patrick W. Serruys et al.   CIRCULATION

Inhibition of lipoprotein-associated phospholipase A2 reduces complex coronary atherosclerotic plaque development

(2008) Robert L Wilensky et al.   NATURE MEDICINE

Enhanced Expression of Lp-PLA 2 and Lysophosphatidylcholine in Symptomatic Carotid Atherosclerotic Plaques

(2008) Dallit Mannheim et al.   STROKE